Will The Vodafone Win Against India’s Income Tax Department Benefit Sanofi In Shantha Deal?
This article was originally published in PharmAsia News
India Supreme Court ruling in Vodafone case may set precedent for offshore acquisitions, but Sanofi-Shantha deal has key differences.
You may also be interested in...
India's Income Tax Department Tightens Noose Over Sanofi-Aventis' Shantha Biotech Deal; Claim Tax On Deal Made Over An "Indian" Asset
MUMBAI - Sanofi-Aventis is faced with more headwinds in India even as it tries to absorb the negative impact of the recent delisting of Shan 5 - its popular pentavalent vaccine - by the World Health Organization
Sanofi Beats GSK To Buy Merieux Alliance's Stake In India's Shantha Biotech; Move Aimed At Stronger Vaccines Business In Emerging Markets
MUMBAI - In a takeover battle that lasted several months, drug maker Sanofi-Aventis emerged winner beating global rival GlaxoSmithKline among others to lap up a majority equity stake in India's Shantha Biotechnics from fellow French pharmaceutical firm Merieux Alliance. Shantha Biotechnics was valued at €550 million ($750 million) on expected sales of €90 million for the current financial year
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.